Kiniksa Pharmaceuticals International, plc (KNSA) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value

Kiniksa Pharmaceuticals International, plc Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value

Kiniksa Pharmaceuticals International, plc (KNSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $12.27 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2024-02-28

• Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $12.27, a 9.31% decline from fiscal 2022.
• Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $13.53, a 23.47% decline from fiscal 2021.
• Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2021 was $17.68, a 35.06% increase from fiscal 2020.
• Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2020 was $13.09.